All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

America on GLP-1

An estimated 14,250,116 US adults use GLP-1 medications for weight management. We break that total down to every county using CDC obesity prevalence and Census population, anchored to the KFF 2024 figure that one in eight US adults has taken a GLP-1.

Last reviewed |Reviewed by the FormBlends Editorial Standards Team

14,250,116

Estimated US users

Educational only. This page is not medical advice. Talk to a licensed clinician about your situation before starting, stopping, or changing any medication. FormBlends only sells compounded semaglutide and tirzepatide; references to other compounds are informational.

5.7%

National adoption rate

Educational only. This page is not medical advice. Talk to a licensed clinician about your situation before starting, stopping, or changing any medication. FormBlends only sells compounded semaglutide and tirzepatide; references to other compounds are informational.

3,144

Counties tracked

Educational only. This page is not medical advice. Talk to a licensed clinician about your situation before starting, stopping, or changing any medication. FormBlends only sells compounded semaglutide and tirzepatide; references to other compounds are informational.

51

States plus DC

Educational only. This page is not medical advice. Talk to a licensed clinician about your situation before starting, stopping, or changing any medication. FormBlends only sells compounded semaglutide and tirzepatide; references to other compounds are informational.

Estimated adoption:<3%3-4%4-5%5-6%6-7%7-8%8%+No data

Which states show the highest estimated GLP-1 use?

Estimated adoption climbs with adult obesity prevalence. In states where 4 in 10 adults have a BMI of 30 or higher, the clinically eligible population is large and the projected user share follows. The chart below shows the 10 highest states in our model.

Top 10 states by estimated GLP-1 adoption rateWest Virginia5.6%Louisiana5.5%Mississippi5.5%Alabama5.4%Arkansas5.4%Indiana5.3%Oklahoma5.3%Iowa5.2%Nebraska5.2%Wisconsin5.2%
Source: FormBlends model, derived from CDC PLACES 2023 and KFF 2024. Click any state below for county-level detail.

State leaderboard

RankStateEst. adoptionEst. usersObesity %Counties
1West Virginia5.6%99,67040.8%55
2Louisiana5.5%253,58240.1%64
3Mississippi5.5%164,17840.8%82
4Alabama5.4%271,54139.7%67
5Arkansas5.4%162,88339.6%75
6Indiana5.3%356,56238.6%92
7Oklahoma5.3%212,32539.3%77
8Iowa5.2%165,94838.2%99
9Nebraska5.2%101,55438.1%93
10Wisconsin5.2%303,72937.9%72

Browse every state

Alabama67Alaska30Arizona15Arkansas75California58Colorado64Connecticut9Delaware3District of Columbia1Florida67Georgia159Hawaii5Idaho44Illinois102Indiana92Iowa99Kansas105Kentucky120Louisiana64Maine16Maryland24Massachusetts14Michigan83Minnesota87Mississippi82Missouri115Montana56Nebraska93Nevada17New Hampshire10New Jersey21New Mexico33New York62North Carolina100North Dakota53Ohio88Oklahoma77Oregon36Pennsylvania67Rhode Island5South Carolina46South Dakota66Tennessee95Texas254Utah29Vermont14Virginia133Washington39West Virginia55Wisconsin72Wyoming23

How did we build these estimates?

Three public datasets. First, the KFF Health Tracking Poll (May 2024) puts GLP-1 use at 12% of US adults ever-taken, 5.7% active. Second, CDC PLACES (2023 release) gives age-adjusted adult obesity prevalence for every county. Third, Census ACS 5-year (2022) gives county population, table B01003_001E.

We anchor the national adoption rate to 5.7%. National average obesity is 41.9% per NHANES 2021-2023 (CDC), so the scaling factor k = 5.7 / 41.9 ≈ 0.1361. County estimated adoption % equals k times the county's obesity %. Multiply by county population to get projected users.

This assumes adoption scales linearly with obesity prevalence. It doesn't capture diabetes-only use, insurance access variation, or the pharmacy shortage dynamics that shifted compounded vs brand-name production in 2024 and 2025. Treat the numbers as a rough projection, not a prescription count.

Frequently asked questions

How many Americans actually use GLP-1 drugs?
The KFF Health Tracking Poll (May 2024) put the figure at one in eight US adults who've ever taken a GLP-1, roughly 32 million people. Active users sit closer to 15 million, or about 5.7% of the adult population. That's the number we anchor our map to. Adoption is heaviest among adults with diabetes (4 in 10) and cardiovascular disease (1 in 4).
Where is adoption highest?
Adoption tracks obesity prevalence. The deep-South states (Mississippi, Louisiana, West Virginia, Kentucky) have adult obesity rates above 38% per CDC BRFSS 2024, so our model projects higher per-capita GLP-1 use there. Colorado, Hawaii, and DC sit at the low end, both for obesity and projected adoption. Real adoption also depends on insurance coverage, which is uneven state by state.
Is this real adoption data or an estimate?
Estimate. The only public prescription-level data source is Medicare Part D, which covers a narrow slice of GLP-1 users. We combine two things that are real: county adult obesity prevalence (CDC PLACES, 2023 release, derived from BRFSS) and county population (Census ACS 5-year, 2022). We scale to the KFF national figure. The formula is shown in the methodology section.
Why does the model use obesity as the proxy?
Because that's where the prescription indication lives. Wegovy (semaglutide) and Zepbound (tirzepatide) are FDA-approved for chronic weight management in adults with BMI at least 30, or BMI at least 27 with a weight-related comorbidity. Counties with higher adult obesity have larger clinically eligible populations, so their projected GLP-1 use is higher. The model doesn't capture diabetes-only use, which adds another couple million Americans.
Will the map show brand-name vs. compounded splits?
Not yet. There's no public dataset that separates brand-name Wegovy / Zepbound prescriptions from compounded versions dispensed by 503A or 503B pharmacies. IQVIA tracks some of this but doesn't release it publicly. When the FDA posts county-level 503A shipment data (promised in 2026), we'll layer it on.
Can I share these numbers in a report or article?
Yes. The dataset is published under CC0. Attribute FormBlends and link to the specific county or state page. Please don't rewrap modeled estimates as measured adoption; readers deserve to know the ratio is a projection from obesity prevalence.

Sources

Related reading

cost

Does Insurance Cover Semaglutide for Weight Loss?

Insurance coverage for semaglutide weight loss varies by plan. Most cover Ozempic for diabetes, fewer cover Wegovy for obesity. Learn coverage options.

cost access

Does Insurance Cover Zepbound in 2026? What 847 Prior Authorization Outcomes Tell Us

Most insurance plans cover Zepbound for obesity with prior authorization, but not for cosmetic weight loss. Real coverage rates, denial patterns, and alternatives.

cost access

What Insurance Covers Zepbound for Weight Loss in 2026: The Complete Coverage Map

Which insurance plans cover Zepbound for weight loss, real coverage scenarios, prior authorization requirements, and compounded tirzepatide alternatives.

cost access

What Is the Cheapest Weight Loss Injection Without Insurance in 2026?

Compare real cash prices for weight loss injections without insurance: compounded semaglutide, tirzepatide, liraglutide, and brand-name options.

See if you qualify

The map tells you where GLP-1 use is concentrated. A 2-minute FormBlends assessment tells you whether you're clinically eligible, and what dose makes sense.

Start your assessment

Estimated adoption figures on this page are modeled projections. They aren't measured prescription counts. Content is for information only, not medical advice. FormBlends only dispenses compounded semaglutide and tirzepatide. Talk to a licensed clinician about whether a GLP-1 is right for you. Individual results vary.